Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995.
Information on long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) is limited. In hepatitis B vaccine trials in Amsterdam, New York City, and San Francisco, 362 gay men were followed up to 18 years (1978-1995). The median survival time from seroconversion was 12.1 years (95% confidence interval: 11.4, 12.9). The annual risk of dying increased at a constant rate until 8 years after seroconversion and then leveled off, suggesting a group that is relatively resistant to progression. These data provide a picture of the natural history of HIV-1 infection, especially in the era prior to widespread use of highly effective treatments.
Koblin
B A
BA
The Wolf Szmuness Laboratory of Epidemiology, The New York Blood Center, NY 10021, USA.
van Benthem
B H
BH
Buchbinder
S P
SP
Ren
L
L
Vittinghoff
E
E
Stevens
C E
CE
Coutinho
R A
RA
van Griensven
G J
GJ
D000328:Adult; D015331:Cohort Studies; D015658:HIV Infections / Q000401:mortality*; D006679:HIV Seropositivity; D015497:HIV-1; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D018451:Homosexuality, Male; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D018570:Risk Assessment; D012495:San Francisco / Q000453:epidemiology; D016019:Survival Analysis
D017325:Hepatitis B Vaccines